PubMed:17956865
Annnotations
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-111 | Sentence | denotes | The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. |
| T2 | 112-270 | Sentence | denotes | The signal transducer and activator of transcription 3 (STAT3) is an IL-6-inducible transcription factor that mediates the hepatic acute phase response (APR). |
| T3 | 271-486 | Sentence | denotes | Using gamma-fibrinogen (FBG) as a model of the APR, we investigated the requirement of an IL-6-inducible complex of STAT3 with cyclin-dependent kinase 9 (CDK9) on gamma-FBG expression in HepG2 hepatocarcinoma cells. |
| T4 | 487-670 | Sentence | denotes | IL-6 induces rapid nuclear translocation of Tyr-phosphorylated STAT3 that forms a nuclear complex with CDK9 in nondenaturing co-immunoprecipitation and confocal colocalization assays. |
| T5 | 671-836 | Sentence | denotes | To further understand this interaction, we found that CDK9-STAT3 binding is mediated via both STAT NH2-terminal modulatory and COOH-terminal transactivation domains. |
| T6 | 837-1036 | Sentence | denotes | Both IL-6-inducible gamma-FBG reporter gene and endogenous mRNA expression are significantly decreased after CDK9 inhibition using the potent CDK inhibitor, flavopiridol (FP), or specific CDK9 siRNA. |
| T7 | 1037-1287 | Sentence | denotes | Moreover, chromatin immunoprecipitation (ChIP) experiments revealed an IL-6-inducible STAT3 and CDK9 binding to the proximal gamma-FBG promoter as well as increased loading of RNA Pol II and phospho-Ser2 CTD Pol II on the TATA box and coding regions. |
| T8 | 1288-1489 | Sentence | denotes | Finally, FP specifically and efficiently inhibits association of phospho-Ser2 CTD RNA Pol II on the gamma-FBG promoter, indicating that CDK9 kinase activity mediates IL-6-inducible CTD phosphorylation. |
| T9 | 1490-1684 | Sentence | denotes | Our data indicate that IL-6 induces a STAT3.CDK9 complex mediated by bivalent STAT3 domains and CDK9 kinase activity is necessary for licensing Pol II to enter a transcriptional elongation mode. |
| T10 | 1685-1811 | Sentence | denotes | Therefore, disruption of IL-6 signaling by CDK9 inhibitors could be a potential therapeutic strategy for inflammatory disease. |
Glycosmos6-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 1153-1161 | http://purl.obolibrary.org/obo/MAT_0000491 | denotes | proximal |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-111 | Sentence | denotes | The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. |
| T2 | 112-270 | Sentence | denotes | The signal transducer and activator of transcription 3 (STAT3) is an IL-6-inducible transcription factor that mediates the hepatic acute phase response (APR). |
| T3 | 271-486 | Sentence | denotes | Using gamma-fibrinogen (FBG) as a model of the APR, we investigated the requirement of an IL-6-inducible complex of STAT3 with cyclin-dependent kinase 9 (CDK9) on gamma-FBG expression in HepG2 hepatocarcinoma cells. |
| T4 | 487-670 | Sentence | denotes | IL-6 induces rapid nuclear translocation of Tyr-phosphorylated STAT3 that forms a nuclear complex with CDK9 in nondenaturing co-immunoprecipitation and confocal colocalization assays. |
| T5 | 671-836 | Sentence | denotes | To further understand this interaction, we found that CDK9-STAT3 binding is mediated via both STAT NH2-terminal modulatory and COOH-terminal transactivation domains. |
| T6 | 837-1036 | Sentence | denotes | Both IL-6-inducible gamma-FBG reporter gene and endogenous mRNA expression are significantly decreased after CDK9 inhibition using the potent CDK inhibitor, flavopiridol (FP), or specific CDK9 siRNA. |
| T7 | 1037-1287 | Sentence | denotes | Moreover, chromatin immunoprecipitation (ChIP) experiments revealed an IL-6-inducible STAT3 and CDK9 binding to the proximal gamma-FBG promoter as well as increased loading of RNA Pol II and phospho-Ser2 CTD Pol II on the TATA box and coding regions. |
| T8 | 1288-1489 | Sentence | denotes | Finally, FP specifically and efficiently inhibits association of phospho-Ser2 CTD RNA Pol II on the gamma-FBG promoter, indicating that CDK9 kinase activity mediates IL-6-inducible CTD phosphorylation. |
| T9 | 1490-1684 | Sentence | denotes | Our data indicate that IL-6 induces a STAT3.CDK9 complex mediated by bivalent STAT3 domains and CDK9 kinase activity is necessary for licensing Pol II to enter a transcriptional elongation mode. |
| T10 | 1685-1811 | Sentence | denotes | Therefore, disruption of IL-6 signaling by CDK9 inhibitors could be a potential therapeutic strategy for inflammatory disease. |
| T1 | 0-111 | Sentence | denotes | The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. |
| T2 | 112-270 | Sentence | denotes | The signal transducer and activator of transcription 3 (STAT3) is an IL-6-inducible transcription factor that mediates the hepatic acute phase response (APR). |
| T3 | 271-486 | Sentence | denotes | Using gamma-fibrinogen (FBG) as a model of the APR, we investigated the requirement of an IL-6-inducible complex of STAT3 with cyclin-dependent kinase 9 (CDK9) on gamma-FBG expression in HepG2 hepatocarcinoma cells. |
| T4 | 487-670 | Sentence | denotes | IL-6 induces rapid nuclear translocation of Tyr-phosphorylated STAT3 that forms a nuclear complex with CDK9 in nondenaturing co-immunoprecipitation and confocal colocalization assays. |
| T5 | 671-836 | Sentence | denotes | To further understand this interaction, we found that CDK9-STAT3 binding is mediated via both STAT NH2-terminal modulatory and COOH-terminal transactivation domains. |
| T6 | 837-1036 | Sentence | denotes | Both IL-6-inducible gamma-FBG reporter gene and endogenous mRNA expression are significantly decreased after CDK9 inhibition using the potent CDK inhibitor, flavopiridol (FP), or specific CDK9 siRNA. |
| T7 | 1037-1287 | Sentence | denotes | Moreover, chromatin immunoprecipitation (ChIP) experiments revealed an IL-6-inducible STAT3 and CDK9 binding to the proximal gamma-FBG promoter as well as increased loading of RNA Pol II and phospho-Ser2 CTD Pol II on the TATA box and coding regions. |
| T8 | 1288-1489 | Sentence | denotes | Finally, FP specifically and efficiently inhibits association of phospho-Ser2 CTD RNA Pol II on the gamma-FBG promoter, indicating that CDK9 kinase activity mediates IL-6-inducible CTD phosphorylation. |
| T9 | 1490-1684 | Sentence | denotes | Our data indicate that IL-6 induces a STAT3.CDK9 complex mediated by bivalent STAT3 domains and CDK9 kinase activity is necessary for licensing Pol II to enter a transcriptional elongation mode. |
| T10 | 1685-1811 | Sentence | denotes | Therefore, disruption of IL-6 signaling by CDK9 inhibitors could be a potential therapeutic strategy for inflammatory disease. |
relna
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 26-39 | Protein | denotes | interleukin 6 |
| T2 | 50-54 | Protein | denotes | CDK9 |
| T3 | 55-60 | DNA | denotes | STAT3 |
| T4 | 116-166 | DNA | denotes | signal transducer and activator of transcription 3 |
| T5 | 168-173 | DNA | denotes | STAT3 |
| T6 | 181-185 | Protein | denotes | IL-6 |
| T7 | 243-263 | Protein | denotes | acute phase response |
| T8 | 265-268 | Protein | denotes | APR |
| T9 | 318-321 | Protein | denotes | APR |
| T10 | 387-392 | DNA | denotes | STAT3 |
| T11 | 398-423 | Protein | denotes | cyclin-dependent kinase 9 |
| T12 | 425-429 | Protein | denotes | CDK9 |
| T13 | 487-491 | Protein | denotes | IL-6 |
| T14 | 550-555 | DNA | denotes | STAT3 |
| T15 | 590-594 | Protein | denotes | CDK9 |
| T16 | 725-729 | Protein | denotes | CDK9 |
| T17 | 730-735 | DNA | denotes | STAT3 |
| T18 | 842-846 | Protein | denotes | IL-6 |
| T19 | 946-950 | Protein | denotes | CDK9 |
| T20 | 1025-1029 | Protein | denotes | CDK9 |
| T21 | 1108-1112 | Protein | denotes | IL-6 |
| T22 | 1123-1128 | DNA | denotes | STAT3 |
| T23 | 1133-1137 | Protein | denotes | CDK9 |
| T24 | 1424-1428 | Protein | denotes | CDK9 |
| T25 | 1454-1458 | Protein | denotes | IL-6 |
| T26 | 1513-1517 | Protein | denotes | IL-6 |
| T27 | 1528-1533 | DNA | denotes | STAT3 |
| T28 | 1534-1538 | Protein | denotes | CDK9 |
| T29 | 1586-1590 | Protein | denotes | CDK9 |
| T30 | 1710-1714 | Protein | denotes | IL-6 |
| T31 | 1728-1732 | Protein | denotes | CDK9 |
| R0 | T11 | T10 | linked | cyclin-dependent kinase 9,STAT3 |
| R1 | T15 | T14 | linked | CDK9,STAT3 |
| R2 | T16 | T17 | linked | CDK9,STAT3 |
| R3 | T23 | T22 | linked | CDK9,STAT3 |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 17956865-2#90#94#gene3569 | 361-365 | gene3569 | denotes | IL-6 |
| 17956865-2#116#121#gene6774 | 387-392 | gene6774 | denotes | STAT3 |
| 17956865-2#127#152#gene1025 | 398-423 | gene1025 | denotes | cyclin-dependent kinase 9 |
| 17956865-2#154#158#gene1025 | 425-429 | gene1025 | denotes | CDK9 |
| 17956865-2#193#208#diseaseC2239176 | 464-479 | diseaseC2239176 | denotes | hepatocarcinoma |
| 17956865-9#43#47#gene1025 | 1728-1732 | gene1025 | denotes | CDK9 |
| 17956865-9#105#125#diseaseC1290884 | 1790-1810 | diseaseC1290884 | denotes | inflammatory disease |
| 90#94#gene3569193#208#diseaseC2239176 | 17956865-2#90#94#gene3569 | 17956865-2#193#208#diseaseC2239176 | associated_with | IL-6,hepatocarcinoma |
| 116#121#gene6774193#208#diseaseC2239176 | 17956865-2#116#121#gene6774 | 17956865-2#193#208#diseaseC2239176 | associated_with | STAT3,hepatocarcinoma |
| 127#152#gene1025193#208#diseaseC2239176 | 17956865-2#127#152#gene1025 | 17956865-2#193#208#diseaseC2239176 | associated_with | cyclin-dependent kinase 9,hepatocarcinoma |
| 154#158#gene1025193#208#diseaseC2239176 | 17956865-2#154#158#gene1025 | 17956865-2#193#208#diseaseC2239176 | associated_with | CDK9,hepatocarcinoma |
| 43#47#gene1025105#125#diseaseC1290884 | 17956865-9#43#47#gene1025 | 17956865-9#105#125#diseaseC1290884 | associated_with | CDK9,inflammatory disease |
Anatomy-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 1153-1161 | Body_part | denotes | proximal | http://purl.obolibrary.org/obo/MAT_0000491 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 243-263 | Phenotype | denotes | acute phase response | HP:0033331 |
| T2 | 265-268 | Phenotype | denotes | APR | HP:0033331 |
| T3 | 318-321 | Phenotype | denotes | APR | HP:0033331 |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 1790-1810 | Disease | denotes | inflammatory disease | http://purl.obolibrary.org/obo/MONDO_0021166 |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 72-77 | OrganismTaxon | denotes | human | 9606 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 569-584 | Body_part | denotes | nuclear complex | http://purl.obolibrary.org/obo/UBERON_0007245 |